Topical Bioequivalence For Unlike Emulsions Should Be Tested In Vivo – FDA
Executive Summary
Bioequivalence of topical dermatologic drugs in different emulsions that target the stratum corneum should be determined through in vivo testing, FDA said
You may also be interested in...
GSK Bactroban Generics Petition Cites FDA Topical Bioequivalence Methods
A citizen petition from GlaxoSmithKline seeking to block Bactroban Cream (mupirocin) generics revisits the question of whether generics of topical dermatologic drug products containing different forms of the active ingredient should be approved by FDA
GSK Bactroban Generics Petition Cites FDA Topical Bioequivalence Methods
A citizen petition from GlaxoSmithKline seeking to block Bactroban Cream (mupirocin) generics revisits the question of whether generics of topical dermatologic drug products containing different forms of the active ingredient should be approved by FDA
Highly Variable Drug Bioequivalence Could Be Shown Through Scaling – Cmte.
Bioequivalence for highly variable drugs can be demonstrated using reference scaling in the near term, FDA's Pharmaceutical Science Advisory Committee said